TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
动量输入（同类管理人）：
持有人广度 +12.0% ·
股份流向 -1.4% ·
净新建仓位 +10.7%
· 公式
持有人分散化：持有人数增多，合计持仓比例缩小。
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 875.63K | $561.43M | n/a | −3 |
| Q2 2026 | 189 | +3 | 258.75M | $130.52B | +5 | −3 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | n/a |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | n/a |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | n/a | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | n/a |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | n/a | −2 |
| Q2 2024 | 23 | n/a | 44.78M | $24.75B | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 33.79M | n/a | $13.70B | 0.2% | n/c | 1 | SEC ↗ ×7 |
| 2 | BlackRock ✦ (被动) | 27.33M | n/a | $11.08B | 0.2% | n/c | 1 | SEC ↗ ×22 |
| 3 | State Street Global Advisors ✦ (被动) | 16.48M | -0.3% | $6.69B | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 4 | Capital World Investors ✦ | 9.58M | -13.4% | $3.88B | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 8.11M | -0.1% | $3.27B | 0.2% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (被动) | 5.59M | -9.7% | $2.26B | 0.3% | ▼ Trim | 5 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 5.56M | -40.3% | $2.25B | 0.3% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 3.99M | n/a | $1.62B | 0.1% | n/c | 1 | SEC ↗ ×7 |
| 9 | Fisher Asset Management ✦ | 2.69M | -0.9% | $1.09B | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 10 | PRIMECAP Management ✦ | 2.41M | +3.8% | $975.61M | 0.8% | ▲ Add | 5 | SEC ↗ |
| 11 | Wellington Management ✦ | 1.43M | -10.4% | $579.51M | 0.1% | ▼ Trim | 5 | SEC ↗ ×5 |
| 12 | D. E. Shaw & Co. ✦ | 1.33M | +463.4% | $537.63M | 0.6% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | Arrowstreet Capital ✦ | 1.21M | +84.6% | $490.99M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 1.10M | +809.7% | $444.72M | 0.4% | ▲ Add | 5 | SEC ↗ ×2 |
| 15 | Two Sigma Investments ✦ | 637.12K | +92.3% | $258.33M | 0.5% | ▲ Add | 5 | SEC ↗ |
| 16 | Baillie Gifford ✦ | 504.68K | -0.9% | $204.63M | 0.2% | ▼ Trim | 5 | SEC ↗ ×4 |
| 17 | Renaissance Technologies ✦ | 458.95K | +195.6% | $186.09M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 18 | Marshall Wace ✦ | 371.63K | 新增 | $150.68M | 0.2% | New | 1 | SEC ↗ ×2 |
| 19 | Point72 Asset Management ✦ | 371.34K | +857.1% | $150.56M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 325.72K | +39.5% | $132.07M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 21 | Millennium Management ✦ | 311.00K | +65.0% | $126.10M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 108.69K | -48.1% | $44.07M | 0.0% | ▼ Trim | 5 | SEC ↗ ×6 |
| 23 | Glenview Capital ✦ | 100.00K | 新增 | $40.55M | 1.2% | New | 1 | SEC ↗ |
| 24 | Gotham Asset Management ✦ | 79.76K | +108.0% | $32.34M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 25 | Markel Group ✦ | 49.55K | +10.1% | $20.09M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 26 | Dodge & Cox ✦ | 25.94K | -0.6% | $10.52M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 27 | Duquesne Family Office ✦ | 12.20K | 新增 | $4.95M | 0.1% | New | 1 | SEC ↗ |
| 28 | GAMCO Investors ✦ | 5.29K | +35.0% | $2.14M | 0.0% | ▲ Add | 5 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $150.68M | 0.2% |
| Glenview Capital | $40.55M | 1.2% |
| Duquesne Family Office | $4.95M | 0.1% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 24.30K 股份, $11,944 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 3.73K 股 · $2.29M
Officer · 400 股 · $245,752
Officer, Director · 62 股 · $38,982
Officer, Director · 33 股 · $20,677
Officer, Director · 101 股 · $63,166
Officer, Director · 79 股 · $49,613
Officer, Director · 2.15K 股 · $1.35M
Officer, Director · 1.79K 股 · $1.12M
Officer, Director · 3.01K 股 · $1.89M
Officer, Director · 2.73K 股 · $1.71M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论